key: cord-0939756-v5g9di1s
authors: Ottaiano, Alessandro; Scala, Stefania; D’Alterio, Crescenzo; Trotta, Annamaria; Bello, Annamaria; Rea, Giuseppina; Picone, Carmine; Santorsola, Mariachiara; Petrillo, Antonella; Nasti, Guglielmo
title: Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection
date: 2021-04-29
journal: Ther Adv Med Oncol
DOI: 10.1177/17588359211011455
sha: bdd5ba1a77f8ccde8dbe12a0394200347a2afd0c
doc_id: 939756
cord_uid: v5g9di1s

Herein, we describe three patients affected by metastatic colorectal cancer (mCRC) experiencing infection by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) and reduction of disease burden during coronavirus disease 2019 (COVID-19) course. Insights into tumor-associated angiotensin-converting enzyme (ACE)-2 expression and lymphocyte function suggest a correlation between host/SARS-Cov-2 infection and tumor burden reduction. This may shed new light into (a) the infection mechanism of SARS-CoV-2 virus and (b) the multiple aspects of a composite antiviral immune response with potential paradoxical and unexpected applications.

Colorectal cancer (CRC) is the third cause of cancer-related deaths worldwide. The therapeutic panorama has been enriched by biologic therapies [anti-angiogenic anti-EGFR (epidermal growth factor receptor) drugs] in association with standard chemotherapies (fluorouracil, irinotecan and oxaliplatin). However, the survival of metastatic disease rarely lasts 24 months. 1 In the last year, since SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has spread from Wuhan (China) to worldwide, many oncological patients undergoing COVID-19 (coronavirus disease 2019) experienced, among other effects, treatment delay. In fact, according to several institutional policies, patients positive to molecular pharyngo-nasal swabs cannot undergo restored, or commence, chemotherapy until after three consecutive negative molecular pharyngonasal swabs.

In this scenario, three patients affected by metastatic CRC (mCRC) displayed radiologic reduction of disease burden during their COVID-19 experience. The patients' consent for anonymized publication was obtained and archived in accordance with regulatory authorities.

Patient 1 is a 65-year-old man who received a right hemicolectomy in October 2019. Histologic and genetic examination revealed a pT4apN1b RAS and BRAF wild-type, MSS (microsatellite stable) adenocarcinoma and he presented with liver metastases. Disease stabilization (with no change in tumor size) was obtained after 7 months of first-line chemotherapy FOLFOX/BEVA [oxaliplatin on day 1 at the dose of 85 mg/m 2 as a 2 h infusion, concurrently with leucovorin 400 mg/m 2 , followed by a bolus of 5-fluorouracil 400 mg/m 2 (FU), and a 48 h infusion of 5-fluorouracil 2400 mg/m 2 (FA) and bevacizumab 5 mg/kg (BEVA) on day 1, every 2 weeks] as documented by CT (computed tomography) in August 2020. Following therapy was FU/FA/BEVA every 2 weeks as maintenance/depotentiated treatment, with the last cycle performed on 2 October 2020, for a total of three cycles. Thereafter, he developed

severe COVID-19, from which he recovered in November 2020 when the CT scan showed complete response with regression of hepatic lesions ( Figure 1 ). The immunoglobulin G (IgG) anti-SARS-CoV-2 titer was 1455 U/ml. Patient 2 is a 58-year-old man who underwent a left hemicolectomy in February 2019. The histologic and genetic assessment showed a pT3pN0 RAS mutated, BRAF wild-type, MSS adenocarcinoma. At diagnosis, he presented with three unresectable liver metastatic lesions treated with pre-operative FOLFOX/BEVA (6 months) followed by multiple metastasectomies in November 2019. Thereafter, the patient refused post-operative chemotherapy. In August 2020, he progressed at liver segments VI and VII as documented with CT scan; concomitantly, he developed mild symptomatic COVID-19. CT scan in December 2020 reported reduction of the liver metastatic lesion at segment VII (15.3 × 14.0 mm versus 10.9 × 10.5 mm) and disappearance of the lesion at segment VI ( Figure 1 ). The IgG anti-SARS-CoV-2 titer was 188.40 U/ml.

RAS and BRAF wild-type, MSS adenocarcinoma followed by 6 months adjuvant FOLFOX therapy (oxaliplatin on day 1 at the dose of 85 mg/m 2 as a 2 h infusion, concurrently with leucovorin 400 mg/m 2 , followed by a bolus of FU and a 48 h infusion of FA). In June 2020, the disease progressed on positron emission tomography and CT total-body scan, with multiple measurable nodules on the peritoneum surface (standard uptake value >3) and a small nodule in the right lung. The patient started first-line chemotherapy with FOLFIRI/PANI (irinotecan 180 mg/m 2 on day 1 plus leucovorin 400 mg/m 2 , followed by an FA bolus and an FU infusion, and panitumumab 6 mg/kg on day 1, every 2 weeks). After six cycles, CT scan in September 2020 displayed disease stabilization (with no change in tumor size) and, concomitantly mild COVID-19. She recovered from COVID-19 at the end of October. Unexpected reduction of peritoneal and lung disease was reported at the CT scan following COVID-19 ( Figure 1 ). IgG anti-SARS-CoV-2 titer by Electro-Chemi-Luminescence Immuno Assay (ECLIA) was 1216 U/ml.

SARS-CoV-2 uses the viral spike (S) protein for host-cell attachment and entry through binding of ACE-2 (angiotensin-converting enzyme 2). 2 The host protease furin cleaves the full-length precursor S glycoprotein into two associated polypeptides: S1 and S2. Cleavage of S generates a polybasic Arg-Arg-Ala-Arg carboxyl-terminal sequence on S1 that binds to cell-surface neuropilin-1 (NRP-1) and NRP-2 receptors. Blocking this interaction by ribonucleic acid interference or selective inhibitors reduces SARS-CoV-2 entry and infectivity in cell culture. 3, 4 Although wide distribution of ACE-2 across human tissues, including lung, liver, stomach, ileum, colon, and kidney was reported, 4 alveolar pneumocytes type 2, the SARS-CoV-2 main target cell, actually expressed rather low levels of ACE-2. 4-6 Hence, the SARS-CoV-2 may depend on co-receptor or other auxiliary membrane proteins to facilitate its infection. NRP-1 could represent such an ACE-2-potentiating factor by promoting the interaction of the virus with ACE-2. NRP-1 is expressed in various tissues of the body. 7-9 Thus, we can hypothesize that the SARS-CoV-2 may infect ACE-2/NRP-1-expressing colon-cancer cells, evoking a direct immune response against the infected cells. Moreover, SARS-Cov-2 binding to ACE-2/NRP-1 in CRC cells might provoke cytokine release, which could enable attracting tumor microenvironment (TME) immune cells: this could be sufficient to explain an anti-tumor effect. Furthermore, cross-reactivity with viral antigens may also be involved in T (via T-cell receptor interactions) or NK (natural killer) lymphocytes [via ADCC (antibody-dependent cellular cytotoxicity)] activation against CRC cells. However, the natural immunity lymphocytes (including NK cells), which are non-major-histocompatibility-complex restricted, quickly react toward transformed or antibody-targeted cells (killing via ADCC). SARS-Cov-2 resolution is likely due to the presence of antibodies, which concomitantly eliminate infected cells (via ADCC) and prevent virus entry into new target cells. Further study of the SARS-Cov-2-infected TME (programmed cell-death protein-1/programmed cell-death ligand-1 pathway, tumorinfiltrating lymphocytes (TILs), tumor-associated macrophages, myeloid-derived suppressor cells, intratumoral cytokines patterns, etc.) will be crucial to understand (a) the consequences of eventual viral replication into tumor cells expressing high ACE-2, and (b) the involved lymphocyte sub-populations. In this regard, as a supporting hypothesis, Patients 1, 2, and 3 convincingly expressed ACE-2 [ Figure 2 , panel (a)] and patients 1 and 3 isolated NKs, displaying higher In the period September-October 2020, 60 mCRC patients were observed. Interestingly, seven patients, not included in this report, developed COVID-19, and recovered from it in a median time of 34 days. In February 2021, four patients displayed undetectable humoral response (IgG <0.04 U/ml) and three showed IgG 0.8, 1.1, 3.6 U/ml. Although a detailed clinical-pathological description of this series is beyond the scope of this report, these patients did not show tumor burden reduction.

A characterization of TILs in metastatic tissue is lacking in our report. However, in CRC, there is a strong and repeatable association between microsatellite instability high (MSI-high) and abundant infiltration by CD3+ T cells. Nevertheless, the described patients were MSS. This may suggest that the observed phenomenon is more likely linked to effector cells from innate immunity.

Interestingly, a previous report linked SARS-CoV-2 infection with neoplastic course in Hodgkin lymphoma. 10 Here, we described, for the first time, improvement in mCRC disease in three patients undergoing COVID-19. Our observation may contribute to generate hypotheses on the infection mechanism of the SARS-CoV-2 virus and the multiple aspects of a composite antiviral immune response in cancer patients.

The authors declare that there is no conflict of interest. 

Metastatic colorectal cancer: role of target therapies and future perspectives

Cell entry mechanisms of SARS-CoV-2

Neuropilin-1 is a host factor for SARS-CoV-2 infection

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues

SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)

The expanding role of neuropilin: regulation of transforming growth factor-β and platelet-derived growth factor signaling in the vasculature

Neuropilin-1 expression in cancer and development

SARS-CoV-2-induced remission of Hodgkin lymphoma